Invention:
This technology is a novel method for detecting clotting parameters related to iron-specific hypercoagulation in settings such as sickle cell disease, hemodialysis, mechanical circulatory support and repeated blood transfusions.
Background:
Iron-mediated hypercoagulation is the result of increased plasma concentrations of iron. Utilizing information about the underlying molecular mechanisms of blood clotting recently discovered at the University of Arizona, this technology provides a method for detecting clotting parameters related to iron-specific hypercoagulation present in blood samples taken from patients. This information can then be compared to known values obtained from control samples to make clinical determinations. Patients who are high risk for hypercoagulation can then be subjected to chelation treatment to prevent clotting in organs.
Applications:
- Diagnose iron-mediated hypercoagulability
- Determine the efficacy of treatment for iron-mediated hypercoagulability
- Possible utility in research laboratory settings
Advantages:
- Provides a novel method of making clinical determinations about iron-mediated hypercoagulability
- May be easily incorporated into existing clinical, laboratory, and industry hematology analyzer
Publication:
http://www.ncbi.nlm.nih.gov/pubmed/26497986
Status: issued U.S. Patent #10,012,659
